


# MeBOP Module 2

## Introduction



UNIVERSITÉ  
DE GENÈVE

**Karine Frenal:**  
The expert of Toxo glideosome and IMC



**Damien Jacot:**  
Expert in ... about everything...




**Sunil Kumar Dogga:**  
TgAsp3




**Budhaditya Mukherjee:**  
Biochemistry

# Apicomplexans are human and animal pathogens




# Malaria

- Caused by
  - *Plasmodium falciparum*
  - *P. vivax*
  - *P. malariae*
  - *P. ovale*
  - *P. knowlesi*
- At risk
  - More than 40% of the world population
- Deaths
  - Around 0.7 million per year
- Malaria
  - Fever
  - Anaemia
  - Metabolic dysfunctions : acidosis, hypoglycemia ...






# *Plasmodium falciparum* life cycle



# *Plasmodium falciparum* erythrocytic stages








**Feeding phase**

**Replication phase**



**Egress & Invasion phase**

# *Plasmodium falciparum* erythrocytic stages



0-5h Rings



5-10h  
Early trophozoite

10-20h  
Mid-Late Trophozoite

>40h Schizont



# Apicomplexan invasive tachyzoite and merozoite



Adapted from Frenal K *et al* (2013) Traffic

# THE GOOD, THE BAD & THE UGLY

*Toxoplasma gondii*

*Plasmodium berghei*

*Plasmodium falciparum*

Model organism

Mouse malaria

Human malaria

Easy genetics

“Easy” genetics

Tricky genetics

“good looking”

*In vivo* only

Relevant

Easy to grow

Full life cycle  
accessible

# Aspartic endopeptidases (ASP/PM)


- ✓ Present in **all eukaryotes**
- ✓ **Broad range of roles :**
  - protein degradation
  - enzyme maturation
  - signal transduction
  - virulence factors




- ✓ Use Asp residues in the motifs **DTG** or **DSG**
- ✓ **Pro-region inactivates enzyme**
- ✓ **Proteolytic maturation leads to activation**



# Mode of action




# Apicomplexan ASPs follow 6 distinct groups



# *Plasmodium falciparum* Plasmepsins


10 aspartic proteases: PfPMI-PfPMX

7 expressed during the erythrocytic stages





# Hemoglobin degradation




- A massive catabolic process.
- Consumes  $\approx 75\%$  of the infected cell Hb, which provides an important source of amino acids for the parasite growth and maturation
- In an acidic food vacuole
- Catalyzed by four aspartic proteases (plasmepsins), three cysteine proteases (falcipains) and one metalloprotease (falcilicin)




**→ Drug target?**

“The way you cut your meat reflects the way you live” – Confucius



“The way you cut your meat reflects the way you live”  
– Confucius







# *Plasmodium falciparum* Plasmepsins

10 aspartic proteases: PfPMI-PfPMX

7 expressed during the erythrocytic stages



# Aspartyl proteases implicated in protein export in *P. falciparum*



PEXEL/HT motif

R/KxLxE/Q/D

**PfPMV - Plasmepsin V**

Boddey *et al*, Nature, 2010

Russo *et al*, Nature, 2010

Homologue in *T. gondii*

RxLxE/D

**TgASP5 - Aspartyl  
Protease 5**


Hsiao *et al*, Traffic, 2013

Curt-Varesano *et al*, Cell microbial, 2015











Hammoudi *et al*, PLoS pathogens, 2015

Coffey *et al*, eLife, 2015

# Plasmepsins' expression throughout the life cycle









# *Plasmodium falciparum* Plasmepsins


		KO viable	Phenotype
PfPMI		✓	None
PfPMII		✓	None
PfHAP		✓	None
PfPMIV		✓	None
PfPMV		✗	Asexual growth
PfPMIX		?	?
PfPMX		?	?
PfPMVI		✓	Oocyst
PfPMVII		✓	None
PfPMVIII		?	?




# PMIX localizes at the apical end of merozoites



# PfPMIX-Ty-Lox expression/excision



# PMIX is critical for blood stages development




# *Toxoplasma gondii* ASPs

**TgASP3**


**PMIX**

**PMX**











# Asp3 is a 'post-Golgi' resident protease




# Tet-inducible knock-down of ASP3



# TgAsp3 is critical for Toxo lytic cycle



# hydroxyethylamine scaffold-based drug 49c



## Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold

Claire-Lise Ciana<sup>a</sup>, Romain Siegrist<sup>a</sup>, Hamed Aissaoui<sup>a</sup>, Léo Marx<sup>a</sup>, Sophie Racine<sup>a</sup>, Solange Meyer<sup>a</sup>, Christoph Binkert<sup>a</sup>, Ruben de Kanter<sup>a</sup>, Christoph Fischli<sup>b,c</sup>, Sergio Wittlin<sup>b,c</sup>, Christoph Boss<sup>a,\*</sup>

<sup>a</sup>Acadon Pharmaceuticals Ltd, Drug Discovery Chemistry and Biology, Hegelheimermattweg 91, CH-4123 Allschwil/BL, Switzerland

<sup>b</sup>Swiss Tropical and Public Health Institute, Parasite Chemotherapy, Socinstrasse 57, CH-4002 Basel, Switzerland

<sup>c</sup>University of Basel, CH-4003 Basel, Switzerland

**Table 2**

In vitro anti-malarial activity of hydroxy-ethyl-amine compounds: optimization of the acid part

Entry	Compound	R	IC <sub>50</sub> NF <sub>54</sub> alb 72 h (nM)	IC <sub>50</sub> NF <sub>54</sub> ser 72 h (nM)	IC <sub>50</sub> NF <sub>54</sub> alb 24 h (nM)	IC <sub>50</sub> NF <sub>54</sub> alb 48 h (nM)	IC <sub>50</sub> P. berghei 24 h (nM)	MLM (µl/ min mg)
1	26	3-CON <sup>t</sup> Pr <sub>2</sub>	2.0	10	>500	<3.1	>500	>1250
2	49a	4-CON <sup>t</sup> Pr <sub>2</sub>	1.6	6.5	>500	—	>500	>1250
3	49b	2-CON <sup>t</sup> Pr <sub>2</sub>	>500	>500	—	—	—	—
4	49c	4-CO-Me-piperazine	0.6	<0.6	>500	—	>500	75
5	49d	3-CO-Me-piperazine	98	102	—	—	—	—
6	49e	3-SO <sub>2</sub> -Me-piperazine	—	138	—	—	—	908
7	49f	4-CO-piperidine	—	1.3	—	—	>500	860
8	49g	3-CO-pyrrolidine	4.9	9.3	—	—	—	—
9	49h	3-CO-azepane	3.8	13	—	—	—	—
10	49i	4-CONH <sup>t</sup> Pr	12	30	—	—	—	—
11	49j	4-Me-piperazine	8.7	8.5	>500	—	>500	80
12	49k	3-Me-piperazine	190	300	—	—	—	—


Low IC<sub>50</sub> at 72 hr

High IC<sub>50</sub> at 24hr



# hydroxy-ethyl-amine scaffold-based drug 49c


IC<sub>50</sub> (24 hours) >500 nM, IC<sub>50</sub> (72 hours) 0.6 nM




Ciana et al. 2013

- Peptidomimetic inhibitor of aspartic proteases
- Designed to target *Plasmodium* food vacuole aspartyl proteases
- “slow” acting drug and dropped...

# Compound 49c efficiently blocks Toxo lytic cycle



IC<sub>50</sub> 650 nM (4 days)



## What we want!

- Functional characterization of PfPMIX
- Functional characterization of TgAsp3
- Molecular targets of compound 49c